Advisory Board January 9, 2023
FDA on Friday issued accelerated approval to lecanemab, an experimental Alzheimer’s drug developed by Eisai and Biogen, for certain Alzheimer’s patients. But many experts say that until the drug is covered by Medicare, its high price tag will prevent many patients from accessing it.
Radio Advisory episode: The ripple effects of Alzheimer’s research fraud
Background
Similar to Aduhelm, lecanemab reduces abnormal clumps of beta amyloid in patients’ brains, proteins that are typically a sign of Alzheimer’s disease.
In a study published in the New England Journal of Medicine last year, patients who received lecanemab saw 27% slower cognitive decline, which translated to a 0.45 score improvement on the Clinical Dementia Rating sum of boxes, compared to those who received a...
Today's Sponsors
Today's Sponsor